Author

Cyril Abdeddaim

Observed names: Abdeddaim, Cyril, C Abdeddaim, C. Abdeddaim, Cyril Abdedaim, Cyril Abdeddaïm

Observed institutions: Inserm, Centre Hospitalier Universitaire de Lille, Lille’s Cardiology Hospital, Centre Oscar Lambret, Centre d'Investigation Clinique - Innovation Technologique de Lille, Université de Lorraine

ORCID: 0000-0002-3856-6785

Observed ORCID: 0000-0002-3856-6785

OpenAlex ID: A5040102390

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

2020 · Ana Oaknin, Anna V. Tinker, et al. · JAMA Oncology · 373

PDF

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

2023 · Thierry André, Dominique Berton, et al. · JAMA Network Open · 149

PDF

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 116

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

2021 · Thierry Andre, Dominique Berton, et al. · Journal of Clinical Oncology · 102

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

2022 · Pierre Heudel, Jean-Sébastien Frenel, et al. · JAMA Oncology · 73

Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.

2021 · Dominique Berton, Susana N. Banerjee, et al. · Journal of Clinical Oncology · 43

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

2024 · Gilles Freyer, Anne Floquet, et al. · Nature Communications · 41

PDF

Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer

2021 · Ana Oaknin, Anna V Tinker, et al. · Future Oncology · 39

PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients

2023 · Thibault Gauduchon, Maria Kfoury, et al. · Gynecologic Oncology · 36

Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery

2021 · H. El Hajj, M. Vanseymortier, et al. · ESMO Open · 31

PDF

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

2025 · Max Piffoux, Alexandra Leary, et al. · Nature Communications · 20

PDF

Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma

2021 · Emeline Guiard, Florian Clatot, et al. · European Journal of Cancer · 20

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

2020 · F. Derquin, A. Floquet, et al. · Gynecologic Oncology · 20

PDF

The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer

2022 · François Cherifi, Sophie Lefevre Arbogast, et al. · Frontiers in Oncology · 18

PDF

Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.

2021 · Felix Blanc-Durand, Elisa Yaniz, et al. · Journal of Clinical Oncology · 18

Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study

2022 · Florence Joly, Michel Fabbro, et al. · Gynecologic Oncology · 14

Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients

2021 · Petr Szturz, Marie Vinches, et al. · European Journal of Cancer · 11

Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer

2022 · Abel Cordoba, Benedicte Durand, et al. · Frontiers in Oncology · 10

PDF

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study

2026 · Barbara Burtness, Ari J. Rosenberg, et al. · Journal of Clinical Oncology · 8

Abstract CT005: Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial

2022 · Benoit You, Alexandra Leary, et al. · Cancer Research · 8

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

2022 · Isabelle Laure Ray-Coquard, Nicolas Penel, et al. · Journal of Clinical Oncology · 8

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

2021 · Olivier Trédan, Magali Provansal, et al. · Gynecologic Oncology · 8

PDF

733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study

2021 · G. Freyer, A. Floquet, et al. · Annals of Oncology · 8

Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

2021 · Pierre-Etienne Heudel, Jean-Sebastien Frenel, et al. · Journal of Clinical Oncology · 7

Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

2025 · Olivia Le Saux, Renaud Sabatier, et al. · Therapeutic Advances in Medical Oncology · 6

Works count: 75

Citation count: 1,252

H-index: 15

I10-index: 18